Ultime notizie per Kamada (NASDAQ:KMDA) Azioni

Kamada

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Kamada Ltd

General

KMDA

Kamada Launches Post-Marketing Research Program For CYTOGAM

Benchmark analyst Robert Wasserman initiates coverage on Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) with a Buy rating and announces Price Target of $15.

News

Price Target

Initiation

Analyst Ratings

Benchmark Initiates Coverage On Kamada with Buy Rating, Announces Price Target of $15

Kamada Opens New Plasma Collection Center With Planned Annual Collection Capacity Of Approximately 50,000 Liters; Estimates Annual Revenue Contribution From Sales Of Normal Source Plasma  $8M-$10M At Full Capacity

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.
Shares of Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) fell sharply in today's pre-market trading after reporting topline results from two Phase 3 clinical trials of Povorcitinib in patients with Hidradenitis Suppurativa.
Incyte shares dipped 15.3% to $57.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) fell 13.8% to $16.00 in pre-market trading after jumping over 70% on Friday.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) dipped 12.1% to $44.01 in pre-market trading after gaining around 7% on Friday.</li>
<li>Tyra Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) fell 8.7% to $10.50 in pre-market trading after gaining 7% on Friday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares dipped 4.4% to $8.05 in pre-market trading after gaining 7% on Friday.</li>
<li>Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) fell 3.8% to $8.71 in pre-market trading.</li>
<li>Innventure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INV#NASDAQ">INV</a>) slipped 3.3% to $7.62 in pre-market trading.</li>
<li>Kamada Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) fell 3% to $6.77 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) slipped 1% to $ 247.77 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38311966/izea-worldwide-and-2-other-stocks-under-3-insiders-are-buying">IZEA Worldwide And 2 Other Stocks Under $3 Insiders Are Buying</a></li>
</ul>
Photo: Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

AFRM

INCY

NEOG

OMER

TSLA

TYRA

USAR

Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) with a Buy and maintains $11 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target

WIIM

Kamada shares are trading higher after the company reported better-than-expected Q4 EPS results and issued FY25 revenue guidance above estimates. Additionally, the company board approved a $0.20 per share special dividend.

Fiscal 2025 Guidance Kamada continues to expect to generate fiscal year 2025 total revenues in the range of $178 million to $182 million, and adjusted EBITDA in the range of $38 million to $42 million, representing a year-over-year increase of approximately 12% in revenues and 17% in adjusted EBITDA based on the mid-point of the 2025 guidance.

Guidance

Kamada Reiterated FY25 Revenue Of $178M-$182M Vs $175.87M Est

Kamada Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>, TASE: KMDA.TA))), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that its Board of Directors has declared a special cash dividend of $0.20 (approximately NIS0.72) per share on the Company's ordinary shares (totaling approximately $11.5 million). The special cash dividend will be payable on April 7, 2025, to shareholders of record at the close of business on March 17, 2025.
 &nbsp;

Dividends

Kamada Board Approved Special Dividend Of $0.20/Share

Earnings

Earnings Beats

Earnings Misses

Kamada Q4 2024 GAAP EPS $0.07 Beats $0.05 Estimate, Sales $39.005M Miss $39.447M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Full Truck Alliance Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YMM#NYSE">YMM</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $419.04 million. 
• Brown Forman Inc Class B Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is projected to report quarterly earnings at $0.46 per share on revenue of $1.07 billion. 
• CLPS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPS#NASDAQ">CLPS</a>) is estimated to report earnings for its first quarter. 
• EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) is expected to report quarterly loss at $0.48 per share on revenue of $11.02 million. 
• Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) is estimated to report quarterly earnings at $0.06 per share on revenue of $39.59 million. 
• Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) is expected to report quarterly loss at $0.58 per share on revenue of $19.97 million. 
• Hydrofarm Holdings Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYFM#NASDAQ">HYFM</a>) is likely to report quarterly loss at $2.00 per share on revenue of $41.10 million. 
• Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $300 thousand. 
• Global Ship Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSL#NYSE">GSL</a>) is projected to report quarterly earnings at $2.54 per share on revenue of $171.17 million. 
• Broadwind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWEN#NASDAQ">BWEN</a>) is expected to report quarterly loss at $0.07 per share on revenue of $31.90 million. 
• Thor Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $1.97 billion. 
• Caesarstone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTE#NASDAQ">CSTE</a>) is expected to report quarterly loss at $0.23 per share on revenue of $99.40 million. 
• REV Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $492.77 million. 
• Daktronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAKT#NASDAQ">DAKT</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $183.46 million. 
• Campbell`s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) is likely to report quarterly earnings at $0.73 per share on revenue of $2.74 billion. 
• Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $110.00 million. 
• VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $30.41 million. 
• OppFi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPFI#NYSE">OPFI</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $133.50 million. 
• Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $90.36 million. 
• Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) is projected to report quarterly earnings at $1.35 per share on revenue of $201.09 million. 
• SmartRent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) is projected to report quarterly loss at $0.03 per share on revenue of $37.78 million. 
• Arbe Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $500 thousand. 
• Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) is likely to report quarterly earnings at $3.29 per share on revenue of $1.52 billion. 
• Brown Forman Inc Class A Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is estimated to report earnings for its third quarter. 
• Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) is projected to report quarterly earnings at $0.73 per share on revenue of $2.32 billion. 
• Stratasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSYS#NASDAQ">SSYS</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $149.88 million. 
<h3>Companies Reporting After The Bell</h3>
• Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) is projected to report quarterly earnings at $0.69 per share on revenue of $635.56 million. 
• Ring Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REI#AMEX">REI</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $86.72 million. 
• Vermilion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VET#NYSE">VET</a>) is likely to report quarterly earnings at $1.67 per share on revenue of $507.35 million. 
• Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $62.00 million. 
• FRP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPH#NASDAQ">FRPH</a>) is likely to report earnings for its fourth quarter. 
• MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $172.52 million. 
• Miller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLR#NYSE">MLR</a>) is likely to report quarterly earnings at $1.09 per share on revenue of $290.30 million. 
• Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) is estimated to report quarterly earnings at $0.21 per share on revenue of $128.69 million. 
• CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $102.50 million. 
• Alto Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTO#NASDAQ">ALTO</a>) is projected to report quarterly loss at $0.11 per share on revenue of $222.81 million. 
• Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) is projected to report quarterly loss at $481.50 per share on revenue of $400 thousand. 
• Park-Ohio Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PKOH#NASDAQ">PKOH</a>) is projected to report quarterly earnings at $0.62 per share on revenue of $405.85 million. 
• NACCO Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NC#NYSE">NC</a>) is expected to report earnings for its fourth quarter. 
• Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) is projected to report quarterly loss at $0.06 per share on revenue of $2.50 million. 
• Forge Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>) is likely to report quarterly loss at $0.09 per share on revenue of $20.75 million. 
• Alta Equipment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) is projected to report quarterly loss at $0.25 per share on revenue of $489.80 million. 
• Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $112.77 million. 
• Methode Electronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) is projected to report quarterly loss at $0.10 per share on revenue of $262.60 million. 
• Ballys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) is likely to report quarterly loss at $0.17 per share on revenue of $612.38 million. 
• NN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNBR#NASDAQ">NNBR</a>) is likely to report quarterly loss at $0.06 per share on revenue of $108.60 million. 
• Climb Global Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMB#NASDAQ">CLMB</a>) is likely to report quarterly earnings at $1.12 per share on revenue of $114.37 million. 
• Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) is expected to report quarterly loss at $0.13 per share on revenue of $13.13 million. 
• Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) is likely to report quarterly loss at $0.20 per share on revenue of $6.12 million. 
• Aware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWRE#NASDAQ">AWRE</a>) is likely to report earnings for its fourth quarter. 
• LivePerson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) is likely to report quarterly loss at $0.05 per share on revenue of $68.13 million. 
• TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $26.68 million. 
• Allient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNT#NASDAQ">ALNT</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $119.71 million. 
• ACRES Commercial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACR#NYSE">ACR</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $22.75 million. 
• Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $20.29 million. 
• Rayonier Adv Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAM#NYSE">RYAM</a>) is expected to report quarterly loss at $0.19 per share on revenue of $418.50 million. 
• Amplify Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPY#NYSE">AMPY</a>) is projected to report quarterly earnings at $0.31 per share on revenue of $76.54 million. 
• Grindr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $90.74 million. 
• LendingTree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) is estimated to report quarterly earnings at $0.63 per share on revenue of $237.32 million. 
• Sleep Number (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNBR#NASDAQ">SNBR</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $389.75 million. 
• Fortuna Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSM#NYSE">FSM</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $308.00 million. 
• Banco BBVA Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAR#NYSE">BBAR</a>) is expected to report earnings for its fourth quarter. 
• Enhabit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHAB#NYSE">EHAB</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $259.11 million. 
• Global Water Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWRS#NASDAQ">GWRS</a>) is estimated to report quarterly earnings at $0.06 per share on revenue of $12.70 million. 
• Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $45.20 million. 
• Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) is expected to report quarterly earnings at $1.58 per share on revenue of $699.27 million. 
• Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) is estimated to report earnings for its fourth quarter. 
• MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) is likely to report quarterly earnings at $0.66 per share on revenue of $519.45 million. 
• Arq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQ#NASDAQ">ARQ</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $25.70 million. 
• Nine Energy Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $135.00 million. 
• Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) is estimated to report quarterly earnings at $0.59 per share on revenue of $1.80 billion. 
• Descartes Systems Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGX#NASDAQ">DSGX</a>) is likely to report quarterly earnings at $0.56 per share on revenue of $169.38 million. 
• Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) is likely to report quarterly earnings at $0.42 per share on revenue of $323.08 million. 
• LandBridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LB#NYSE">LB</a>) is estimated to report quarterly earnings at $0.32 per share on revenue of $38.04 million. 
• Riley Exploration Permian (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REPX#AMEX">REPX</a>) is likely to report quarterly earnings at $1.64 per share on revenue of $105.49 million. 
• Pampa Energia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAM#NYSE">PAM</a>) is expected to report quarterly earnings at $0.72 per share on revenue of $450.71 million. 
• GeoPark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPRK#NYSE">GPRK</a>) is expected to report quarterly earnings at $0.80 per share on revenue of $168.00 million. 
• Orion Office REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONL#NYSE">ONL</a>) is likely to report earnings for its fourth quarter. 
• Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) is likely to report quarterly earnings at $0.13 per share on revenue of $19.62 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALNT

ALTG

ALTO

AMPY

AQST

ARBE

AWRE

BALY

BBAR

BWEN

CLMB

CLPS

CMPO

CSTE

CULP

DAKT

DSGX

EDIT

EHAB

EYPT

FRGE

FRPH

GPRK

GRND

GWRS

HYFM

INVE

LPSN

MRVL

NEXN

NINE

NNBR

OCGN

OPFI

PKOH

REPX

REVG

RGTI

RSKD

RYAM

SGHT

SMRT

SNBR

SSYS

SVCO

TPVG

TREE

VBNK

VEEV

VSCO

YEXT

ZYME

Earnings Scheduled For March 5, 2025

Kamada shares are trading higher after the company announced a contract award for the supply of KAMRAB and VARIZIG in Latin America for 2025-2027.

Kamada announced that it was awarded a contract with an international organization for the supply of KAMRAB and VARIZIG in Latin America for 2025-2027

Kamada shares are trading higher after the company issued FY25 guidance above estimates.

<ul>
<li>Provides 2025 Annual Guidance of $178 - $182 Million in Revenue and $38 -&nbsp;$42 Million of Adjusted EBITDA, Representing Year-Over-Year Increase of 13% in Revenues and 19% in Adjusted EBITDA Based on Mid-Point of 2024 Annual Guidance</li>
<li>Expects to Achieve 2024 Guidance of $158 - $162 Million in Revenue and $32 - $35 Million of Adjusted EBITDA; 2024 Year-End Cash of $78 Million</li>
<li>Aiming to Secure New Business Development and M&amp;A Transactions During 2025 that Leverage Overall Financial Strength and Existing Commercial Infrastructure to Accelerate Long-Term Growth</li>
<li>Expansion of Plasma Collection Operations with Opening of a Third Center by End of Q1 2025</li>
<li>Based on Positive Feedback from U.S. FDA, Kamada Plans to Reduce Inhaled AAT Clinical Study Sample Size to Approximately 180 Patients; Interim Futility Analysis Planned by End of 2025</li>
</ul>

Kamada Reaffirms 2024 Targets, Unveils 2025 Guidances, Revenue Of $178M-$182M Vs. $171.18M Est. And Adj.EBITDA Of $38M-$42M

Kamada Raises FY24 Adjusted EBITDA Guidance To $32M-$35M, A 12% Increase Of The Midpoint From The Previous Guidance, And Reiterates Revenue Guidance Of $158M-$162M Vs. $160.47M Estimate

Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.07 by 157.14 percent. The company reported quarterly sales of $41.740 million which beat the analyst consensus estimate of $40.923 million by 2.00 percent. This is a 10.03 percent increase over sales of $37.934 million the same period last year.

Kamada Q3 2024 GAAP EPS $0.18 Beats $0.07 Estimate, Sales $41.740M Beat $40.923M Estimate

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-11-13. Here's what investors need to know before the announcement.
Analysts estimate that Kamada will report an earnings per share (EPS) of $0.07. 
The announcement from Kamada is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.02, leading to a 0.75% increase in the share price on the subsequent day.
Here's a look at Kamada's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.06</td>
<td>0.06</td>
<td>0.05</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.08</td>
<td>0.04</td>
<td>0.09</td>
<td>0.06</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-3.0%</td>
<td>2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731434822_0.png" alt="eps graph" />
<h3>Kamada Share Price Analysis</h3>
Shares of Kamada were trading at $6.1 as of November 11. Over the last 52-week period, shares are up 31.82%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/KMDA/earnings">To track all earnings releases for Kamada visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: Kamada's Earnings Preview

Press Releases

Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance

Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025

Health Care

Contracts

Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America

Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025

Kamada Declares Special Cash Dividend of $0.20 Per Share

Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth

Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas

Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders

Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025

Benchmark

HC Wainwright & Co.

Stifel

Screenshot 2025-04-21 at 5.40.48 PM

Biotech

Kamada Expects Third Plasma Collection Site To Support Its Hyper-Immune Plasma Needs And Add Up To $10M In Annual Revenue At Full Capacity

Comments

Kamada

Notizie

Ultime notizie per Kamada (NASDAQ:KMDA) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO